On the other hand, Watanabe et al. [9] (on the basis of eight years clinical experience of MGMT immunostaining, using serial sections stained for non-tumour markers such as CD45 and CD68 and a careful algorithmic approach) consider that MGMT immunohistochemistry correlates with outcomes in patients with glioblastomas. The gene discussed is MGMT; the disease is glioblastoma.